| abstract |
Compounds having activity of inhibitors of the G12C mutant KRAS protein are provided, compounds having the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, where R, R, R, R, R, R, G, G, L, L, m, m, A, B, W, X, Y, Z, and E are as defined herein. Also provided are methods associated with the preparation and use of such compounds, pharmaceutical compositions containing such compounds, and methods for modulating the activity of the G12C mutant KRAS protein for the treatment of disorders such as cancer. |